Design: population pharmacokinetic model with allometric scaling, maturation function and dosing simulation
Population: 25 preterm neonates, median gestational age 26.3 weeks, from a phase 1/2a trial
Primary outcome: anakinra clearance and volume of distribution, and simulated dosing to a target exposure
Effect: clearance 3.97 L/h/70 kg; about 45% of maximum at birth, reaching 100% by postnatal day 10

Twenty-five preterm neonates of median 26.3 weeks' gestation, enrolled in a phase 1/2a trial of intravenous anakinra, contributed four to eight samples each over the first 20 days of life. A one-compartment population model with linear elimination and a baseline term for endogenous interleukin-1 receptor antagonist fitted the data.

The maturation finding is the one that matters. Clearance at birth was about 45% of its early postnatal maximum and reached roughly 100% by day 10. A fixed milligram-per-kilogram dose therefore overexposes on day one and underexposes by day ten - the opposite errors at each end of the same week. The simulated regimen escalates accordingly: 0.6 mg/kg twelve-hourly at birth, 0.8 mg/kg on day 1, 1.0 mg/kg on days 2 to 3, and 1.15 mg/kg from day 4.

Anakinra is not standard care for the inflammatory complications of prematurity, and this does not make it so; the parent trial is phase 1/2a. What travels beyond anakinra is the shape of the finding. Protein drug clearance in a 26-week neonate is not a scaled-down adult value, and an escalating schedule over the first postnatal week is a pattern worth expecting whenever a new agent enters this population. Twenty-five neonates is a small model, and the doses are simulated rather than tested.

Clearance at birth was about 45% of its day-10 value in neonates around 26 weeks' gestation.
A fixed mg/kg dose in the first postnatal week overdoses early and underdoses late.
Anakinra remains investigational for prematurity complications; this is phase 1/2a data.
Expect postnatal age, not just weight, to drive dosing for protein drugs in preterm neonates.
The proposed doses come from simulation and have not been tested prospectively.

Why it matters

It replaces an extrapolated adult clearance with a measured neonatal one, in the population where extrapolation goes most wrong.

The statistics, in plain English

A population model with 25 neonates can describe the average maturation curve but not the spread around it, and the between-patient variability is what determines whether a simulated regimen is safe in an individual. Allometric scaling plus a maturation function is the standard approach and a reasonable one, but it is an assumed shape fitted to sparse data rather than an observed one.